ENIGMA-Sleep: Challenges, opportunities, and the road map

This is the peer reviewed version of the following article:
Tahmasian, M., Aleman, A., Andreassen, O. A., Arab, Z., Baillet, M., Benedetti, F.,
Bresser, T., Bright, J., Chee, M. W. L., Chylinski, D., Cheng, W., Deantoni, M., Dresler,
M., Eickhoff, S. B., Eickhoff, C. R., Elvsåshagen, T., Feng, J., Foster-Dingley, J. C.,
Ganjgahi, H., ... Zarei, M. (2021). ENIGMA-Sleep : Challenges, opportunities, and the
road map. *Journal of Sleep Research, 30*(6), p. Article e13347, which has been
published in final form at [https://doi.org/10.1111/jsr.13347](https://doi.org/10.1111/jsr.13347).

This article may be used for non-commercial purposes in accordance with Wiley Terms
and Conditions for Use of Self-Archived Versions. This article may not be enhanced,
enriched or otherwise transformed into a derivative work, without express permission
from Wiley or by statutory rights under applicable legislation. Copyright notices must not
be removed, obscured or modified. The article must be linked to Wiley’s version of
record on Wiley Online Library and any embedding, framing or otherwise making
available the article or pages thereof by third parties from platforms, services and
websites other than Wiley Online Library must be prohibited.
ENIGMA-Sleep: challenges, opportunities, and the road map

Masoud Tahmasian1*, André Aleman2, Ole A. Andreassen3, Zahra Arab1, Marion Baillet4, Francesco Benedetti5,6, Tom Bresser7,8, Joanna Bright9, Michael W. L. Chee10, Daphné Chylinski4, Wei Cheng11,12, Michele Deantoni4, Martin Dresler13, Simon B. Eickhoff14,15, Claudia R. Eickhoff16,17, Torbjørn Elvsåshagen18,19, Jianfeng Feng20,21,22, Jessica C. Foster-Dingley7, Habib Ganjgahi23, Hans J. Grabe24,25, Nynke A. Groenewold26, Tiffani C. Ho27, Seung Bong Hong28, Josselin Houenou29,30,31, Benson Irungu32, Neda Jahanshad33, Habibolah Khazaie34, Hosung Kim35, Ekaterina Koshmanova4, Desi Kocevska7, Peter Kochunov36, Oti Lakkila-Kama17,8, Jeanne Leerssen7,8, Meng Li37,38,39, Annemarie I. Luik40,41, Vincenzo

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/JSR.13347.

This article is protected by copyright. All rights reserved.
Muto\textsuperscript{4}, Justinas Narbutas\textsuperscript{4}, Gustav Nilsonne\textsuperscript{42,43}, Victoria S. O’Callaghan\textsuperscript{44}, Alexander Olsen\textsuperscript{45,46}, Ricardo M. Osorio Suarez\textsuperscript{7,48}, Sara Polett\textsuperscript{i,5,6}, Govinda Poudel\textsuperscript{49}, Joyce E. Reesen\textsuperscript{7,8}, Liesbeth Reneman\textsuperscript{50}, Mathilde Rey\textsuperscript{4,51}, Dieter Riemann\textsuperscript{52}, Ivana Rosenzweig\textsuperscript{53,54}, Masoumeh Rostampour\textsuperscript{34}, Amin Saberi\textsuperscript{1}, Julian Schiel\textsuperscript{52}, Christina Schmidtt\textsuperscript{4,51}, Anouk Schrantee\textsuperscript{50}, Emma Sciberras\textsuperscript{55,56,57}, Tim J. Silk\textsuperscript{55,56,57}, Kang Sim\textsuperscript{58}, Hanne Smievik\textsuperscript{46}, Jair C. Soares\textsuperscript{32}, Kai Spiegelhalder\textsuperscript{52}, Dan J. Stein\textsuperscript{26}, Puneet Talwar\textsuperscript{4}, Sandra Tammy\textsuperscript{41,42,59}, Giana I. Teresi\textsuperscript{60}, Sofie L. Valk\textsuperscript{14,15}, Eus van Someren\textsuperscript{7,8,61}, Gilles Vandewalle\textsuperscript{4}, Maxime Van Egroo\textsuperscript{4}, Henry Völzke\textsuperscript{62,63}, Martin Walter\textsuperscript{39,64,65,66}, Rick Wassing\textsuperscript{7}, Frederik D. Weber\textsuperscript{13}, Antoine Weih\textsuperscript{24}, Lars Tjelta Westlye\textsuperscript{3,67,68}, Margaret J. Wright\textsuperscript{69,44}, Mon-Ju Wu\textsuperscript{70}, Nathalia Zak\textsuperscript{3}, Mojtaba Zarei\textsuperscript{1}

1 Institute of Medical Science and Technology, Shahid Beheshti University, Tehran, Iran.
2 University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands.
3 NORMENT, Division of Mental Health and Addiction, Oslo University Hospital, and Inst of Clinical Medicine, University of Oslo, Oslo, Norway.
4 GIGA-Institute, Cyclotron Research Center/In Vivo Imaging, Sleep and Chronobiology Lab, University of Liège, Liège, Belgium.
5 Psychiatry & Clinical Psychobiology, Division of Neuroscience, IRCCS Scientific Institute Ospedale San Raffaele, Milano, Italy.
6 Vita-Salute San Raffaele University, Milano, Italy.
7 Department of Sleep and Cognition, Netherlands Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105, BA, Amsterdam, Netherlands.
8 Department of Integrative Neurophysiology, Center for Neurogenomics and Cognitive Research (CNCR), Amsterdam Neuroscience, VU University Amsterdam, Amsterdam, Netherlands.
9 Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA.
10 Centre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

This article is protected by copyright. All rights reserved
Institute of Science and Technology for Brain-inspired intelligence, Fudan University, Shanghai, China.

Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence, Ministry of Education, Fudan University, Shanghai, China.

Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, Netherlands.

Institute of Neuroscience and Medicine (INM-7), Research Centre Jülich, Jülich, Germany.

Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, 52428, Germany.

Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, University of Düsseldorf, Düsseldorf, 40225, Germany.

Norwegian Centre for Mental Disorders Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Institute of Science and Technology for Brain-inspired intelligence, Fudan University, Shanghai, China.

Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence, Ministry of Education, Fudan University, Shanghai, China.

Department of Computer Science, University of Warwick, Coventry CV4 7AL, UK.

Department of Statistics, University of Oxford, Oxford, United Kingdom.

Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.

German Center for Neurodegenerative Diseases DZNE, Site Rostock/Greifswald, Greifswald, Germany.
<table>
<thead>
<tr>
<th></th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>SA MRC Unit on Risk &amp; Resilience in Mental Disorders, Department of Psychiatry &amp; Neuroscience Institute, University of Cape Town, Cape Town, South Africa</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Department of Neurology, Samsung Medical Center, SBRI (Samsung Biomedical Research Institute), Sungkyunkwan University School of Medicine, Republic of Korea.</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Centre CEA de Saclay, Neurospin, 91191 Gif-Sur-Yvette Cedex, France.</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>APHP, Hôpitaux Universitaires Mondor, Département IMPACT de Psychiatrie et d'Addictologie 94000 Créteil, France.</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>INSERM U955, IMRB &amp; University Paris Est Créteil, Team 15 « Translational Neuropsychiatry », Fondation FondaMental, Créteil, France.</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Department of Psychiatry &amp; Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA.</td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA.</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Laboratory of Neuro Imaging at USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, 2025 Zonal Ave, Los Angeles, CA 90033, USA.</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Clinical Affective Neuroimaging Laboratory, Otto von Guericke University, Magdeburg, Germany.</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Department of High-field Magnetic Resonance, Max Planck Institute for Biological Cybernetics Tübingen, Tübingen, Germany.</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.</td>
<td></td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved
Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands.

Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands.

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Stress Research Institute, Department of Psychology, Stockholm University, Stockholm, Sweden.

Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia.

Department of Physical Medicine and Rehabilitation, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.

Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway.

Center for Brain Health, Department of Psychiatry, NYU Langone Medical Center, New York, NY USA.

Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.

Mary Mackillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, AMC, Amsterdam, Netherlands.

Psychology and Neuroscience of Cognition Research Unit, Faculty of Psychology and Educational Sciences, University of Liège, Liège, Belgium.

Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.

Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, UK.

Sleep Disorders Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

Department of Paediatrics, University of Melbourne, Parkville, Australia.
56 Murdoch Children’s Research Institute, Parkville, Australia.

57 School of Psychology, Deakin University, Geelong, Australia.

58 Institute of Mental Health, Buangkok Green Medical Park, Buangkok, Singapore.

59 Department of Psychiatry, University of Oxford, Oxford, UK.

60 Department of Psychology, Stanford University, Stanford, CA, USA.

61 Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Neuroscience, Amsterdam, Netherlands.

62 Institute for Community Medicine, Department SHIP/Clinical Epidemiological Research, University Medicine Greifswald, Greifswald, Germany.

63 German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, Greifswald, Germany.

64 Leibniz Institute for Neurobiology, Magdeburg, Germany.

65 Department of Psychiatry and Psychotherapy, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

66 Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.

67 Department of Psychology, University of Oslo, Norway.

68 K.G Jebsen Center for Neurodevelopmental Disorders, University of Oslo, Norway.

69 Centre for Advanced Imaging, The University of Queensland, St Lucia, QLD, 4072, Australia.

70 Department of Psychology and Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minnesota, USA.

* Corresponding author: Masoud Tahmasian M.D., Ph.D., Institute of Medical Science and Technology, Shahid Beheshti University, Daneshjou Boulevard, Velenjak, P.O. Box 1983969411, Tehran, Iran. Telephone: +98-21-29905803; Fax: +98-21-29902650; Email: masoudtahmasian@gmail.com

Running title: The ENIGMA-SLEEP working group

This article is protected by copyright. All rights reserved
Conflict of interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Data Availability Statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Acknowledgments: GN was supported by Riksbankens Jubileumsfond (grant no. P15-0310:1). SLV was supported by the Otto Hahn award of the Max Planck Society. AO was supported by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU). GV and CS are funded by National Funds FNRS Scientific Research (FRS-FNRS Belgium). The research included here was funded by Wallonia-Brussels Federation (ARC - 09/14-03), WELBIO/Walloon Excellence in Life Sciences and Biotechnology Grant (WELBIO-CR-2010-06E), FNRS-Belgium (FRS-FNRS, F.4513.17 & T.0242.19 & 3.4516.11), University of Liège (ULiège), Fondation Simone et Pierre Clerdent, European Regional Development Fund (Radiomed project), European Research Council (ERC-Starting Grant - GA 757763). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIJE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. TCH is supported by the National Institute of Mental Health (K01MH117442) and the Ray and Dagmar Dolby Family Fund. AW was supported by the Deutsche Forschungsgemeinschaft (DFG, grant number: GR 1912/13-1). The Study of Health in Pomerania (SHIP) is supported by the German Federal State of Mecklenburg-West Pomerania. MRI scans have been supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania and PSG assessment was in part supported by the Deutsche RLS e.V. (German Restless Legs Syndrome Society). HJG has received travel grants and speakers honoraria.
from Fresenius Medical Care, Neuraxpharm, Servier and Janssen Cilag as well as research funding from Fresenius Medical Care.

Author contribution: All authors contributed to the drafting and revising of the manuscript.

Abstract

Neuroimaging and genetics studies have advanced our understanding of the neurobiology of sleep and its disorders. However, individual studies usually have limitations to identifying consistent and reproducible effects, including modest sample sizes, heterogeneous clinical characteristics, and varied methodologies. These issues call for a large-scale multi-center effort in sleep research, in order to increase the number of samples, and harmonize the methods of data collection, preprocessing, and analysis using pre-registered well-established protocols. The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium provides a powerful collaborative framework for combining datasets across individual sites. Recently, we have launched the ENIGMA-Sleep working group with the collaboration of several institutes from 15 countries to perform large-scale worldwide neuroimaging and genetics studies for better understanding on the neurobiology of impaired sleep quality in population-based healthy individuals, the neural consequences of sleep deprivation, pathophysiology of sleep disorders, as well as neural correlates of sleep disturbances across various neuropsychiatric disorders. In this introductory review, we describe the details of our currently available datasets and our ongoing projects in the ENIGMA-Sleep group, and discuss both the potential challenges and opportunities of a collaborative initiative in sleep medicine.

Keywords: Sleep, Neuroimaging, Neurogenetics, Large-Scale Collaboration, ENIGMA Consortium

“Everyone sleeps, except lovers, who stay awake, telling stories to God” (Rumi).

1. Introduction

This article is protected by copyright. All rights reserved
The role of sleep in human evolution remains mysterious (Nunn, Samson, & Krystal, 2016), but it is well known that sleep plays a pivotal role in synaptic plasticity, memory consolidation, metabolite and hormonal regulation, adaptive cognitive and emotional functions, individual performance and overall well-being and health (Leproult & Van Cauter, 2010; Shattuck, Matsangas, Mysliwiec, & Creamer, 2019; Stickgold, 2005; Walker, 2009; Xie et al., 2013). Nowadays, a substantial number of people suffer from inadequate sleep and various sleep disorders, which in addition to the genetics, psycho-social and developmental factors, can to some extent be attributed to excessive stressful life-events, the 24/7 rhythm of the modern world, shift-work, and significant amount of entertainment and media consumption before sleep (Grandner, 2017). Sleep disturbances are associated with diverse physical health issues and medical conditions such as hypertension, obesity, cardiovascular diseases, metabolic diseases, motor vehicle collisions, and low quality of life (Cappuccio & Miller, 2017; Medic, Wille, & Hemels, 2017; Ohayon, Lemoine, Arnaud-Briant, & Dreyfus, 2002). In addition, sleep disturbances have a robust link with cognitive and emotional impairment in healthy subjects and are common in patients with various neuropsychiatric disorders including dementia, Parkinson disease, major depressive disorder, bipolar disorder, post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD), or anxiety disorders (Baglioni et al., 2016; Bucks, Olaith, Rosenzweig, & Morrell, 2017; Durmer & Dingess, 2005; Dyken, Afifi, & Lin-Dyken, 2012; Freeman, Sheaves, Waite, Harvey, & Harrison, 2020; Harvey, Murray, Chandler, & Soehner, 2011; Macedo, Balouch, & Tabet, 2017; Morin et al., 2015; Nedergaard & Goldman, 2020; Poudel, Innes, & Jones, 2013; Rosenzweig et al., 2015; Tahmasian et al., 2020). However, despite a high prevalence of sleep problems (e.g., insomnia symptoms in 30-35% and insomnia disorder in 10% of the general population) and their high socioeconomic burden (Morin et al., 2015), the underlying neural mechanisms of sleep disorders, neurobiological consequences of sleep deprivation, as well as the link between sleep disturbances and a variety of neuropsychiatric disorders are poorly understood.

We recently launched a sleep working group in the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium, in order to perform coordinated multi-center neuroimaging and genetics studies on the field of sleep medicine. In the present article, we will discuss the challenges and opportunities in this field, and highlight the need for such a worldwide collaborative approach to tackle them in the ENIGMA-Sleep working group framework.

2. Why is an international collaboration needed?
Sleep has been the subject of numerous studies utilizing state-of-the-art genetic, behavioral, and brain imaging approaches in the general population, healthy subjects with experimental sleep deprivation, or patients with sleep disorders (Freeman et al., 2020; Jansen et al., 2019; Krause et al., 2017; Poudel, Innes, & Jones, 2018; Tahmasian et al., 2020). One of the promising goals of these studies is to improve our understanding of the neurobiological underpinnings of these sleep disturbances. However, historically, most of the studies have had limited statistical power, and were poorly replicated, predominantly due to small sample sizes, diversity of imaging acquisition, preprocessing, and analytic methods used, as well as due to heterogeneous, and often not so well-defined clinical populations (Button et al., 2013). Most importantly, due to the finite funding, resources, and availability of volunteers, many of the individual studies have small sample sizes (see the included studies in some recent sleep-related neuroimaging meta-analyses; (Javaheripour et al., 2019; Tahmasian, Noori, et al., 2018)). As a consequence of low power, small and subtle effects are less likely to be identified, resulting in a lower positive predictive value and higher probability of reporting false positive results (Ioannidis, 2005). On the other hand, it is difficult to publish non-significant results, contributing to the publication bias and creating further problems for interpreting the results of individual studies (Franco, Malhotra, & Simonovits, 2014). In addition, due to the higher demand for publishing significant findings as much/soon as possible, when researchers get non-significant results, they are sometimes incentivized to apply more liberal analytic methods, or try post-hoc modifications of pre-planned methods that may identify statistical significance (Poldrack et al., 2017).

Coordinate- or image-based neuroimaging meta-analyses (CBMA, IBMA) have become increasingly popular approaches that can transcend the limitations of individual single studies by retrospectively synthesizing the findings of the previously published literature (Laird et al., 2009; Müller et al., 2018; Salimi-Khorshidi, Smith, Keltner, Wager, & Nichols, 2009; Tahmasian et al., 2019). Recently, several coordinate-based meta-analyses on sleep deprivation (Javaheripour et al., 2019; Ma, Dinges, Basner, & Rao, 2015; Saletin, Jackvony, Rodriguez, & Dickstein, 2019), insomnia disorder (Jiang, He, Guo, & Gao, 2020; Tahmasian, Noori, et al., 2018; Wu, Zhuang, & Qi, 2020), obstructive sleep apnea (OSA) (Huang, Tang, Lu, Yang, & Chen, 2019; Shi et al., 2017; Tahmasian et al., 2016; Weng et al., 2014), narcolepsy (Weng et al., 2015), and restless leg syndrome (RLS) (Sheng et al., 2020) reported converging regional brain abnormalities across available original studies. However, the findings of these meta-analyses are also divergent because of their heterogeneity in search strategies, included samples, and meta-analytical flexibility (Müller et al., 2018; Tahmasian et al., 2019). In particular, unlike ENIGMA’s prospective meta-analyses (c.f. section 3), the conventional retrospective meta-analyses often include
studies with diverse methods/populations and need to weigh-up the importance of homogeneity on the one hand, and the number of their included studies on the other (Tahmasian, Zarei, et al., 2018). Furthermore, non-significant findings are less likely to get published and are therefore not included in many CBMAs, which leads to over-representation of positive findings in meta-analyses’ results. These limitations of both individual and retrospective, literature-based meta-analytic studies and the notable divergence in their findings substantially hinder our understanding of the neurobiology of sleep. There is a need to form collaborations and together, perform high-powered studies. In the absence of expensive large-scale coordinated multi-site data collection studies planned prospectively, a coordinated effort to pool retrospectively collected information across studies is feasible. By harmonizing existing data and methodologies, we can aim to determine the source of the divergent findings in the literature, and present a common brain signature for the disorders across heterogeneous populations. The initial strides towards this goal may be accomplished by recruiting internationally representative clinical populations, pre-registration of analysis plans, and standardization of processing pipelines, which altogether call for large-scale collaborations in sleep neuroimaging studies.

Accordingly, we need a consensus approach, which has not previously been established in sleep medicine research. Of note, there have been a few large-scale studies on neuroimaging/genetics of sleep, owing to big data initiatives such as Lifebrain, UK Biobank, Enhanced Nathan Kline Institute (eNKI), or the Human Connectome Project. These datasets usually contain subjective information about the sleep quality and quantity from their participants. For example, see (Fjell et al., 2020; Jansen et al., 2019; Toschi, Passamonti, & Bellesi, 2020). However, these large neuroimaging data initiatives are multipurpose and often lack specific sleep assessments using e.g., well-established sleep questionnaires, actigraphy, and polysomnography ( PSG). They usually have not specifically diagnosed patients with sleep disorders based on psychiatric interviews using Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Sleep Disorders (ICSD).

3. **ENIGMA consortium**

The ENIGMA consortium is a worldwide collaboration of more than 1400 scientists from more than 200 institutes, across 45 countries, which started in 2009 and to date have performed many large-scale neuroimaging and genetics mega- and meta-analyses by pooling data across the whole world (Thompson et al., 2020). Currently, the ENIGMA consortium has more than 50 working groups consisting...
of clinicians, neuroscientists, neuroimaging methodologists and other worldwide experts to study healthy brain variations, various neuropsychiatric disorders, or develop imaging techniques (Bas-Hoogendam et al., 2020; Dennis et al., 2020; Schmaal et al., 2020; Thompson et al., 2020; van den Heuvel et al., 2020). Meta- and mega-analyses are the two common types of studies performed by the ENIGMA groups. In prospective meta-analyses, identical and standardized experimental/analytical protocols are used in each institute/center, and the resulting group-level statistics are shared and pooled across them. This approach is analytically quite similar to the conventional literature-based retrospective meta-analyses, but it reduces the effects of heterogeneity and publication bias, which are common in conventional meta-analyses, by virtue of using standardized protocols and being prospective. The ENIGMA’s meta-analytic studies allow for an increased number of participating sites by eliminating the need for sharing individual raw data, which might be subject to legislative, ethical, or personal prohibitions. In ENIGMA’s mega-analyses, the raw or processed (e.g., cortical thickness of brain areas) individual data is shared and pooled across the sites, leading to a potentially higher power and greater flexibility (e.g., by enabling us to apply machine learning methods which require individual data), at the cost of lower number of participating sites, and more computational/storage requirements at the pooling site (Zugman et al., 2020). Sites not able to share individual level measures can then participate as part of replication attempts.

4. Launching ENIGMA-Sleep working group

Recently, the ENIGMA-Sleep working group was formed by a collaboration of several scientists from several institutes across 15 countries (Fig. 1), as the largest neuroimaging collaboration focusing on neuroimaging of sleep and sleep disorders. Here, we will discuss the road map, open questions, challenges, and opportunities of the ENIGMA-Sleep working group in the field of sleep and neuroimaging. The overall aim of this group is to identify reproducible neural mechanisms of sleep and sleep disorders. Currently, the ENIGMA-Sleep working group focuses on assessing neural correlates of subjective and objective sleep quality/quantity in healthy subjects, adaptive/maladaptive brain reorganization due to experimental sleep deprivation or sleep disturbances, studying sleep patterns and their consequences during lifespan, as well as identifying structural and functional alterations in sleep disorders using multimodal neuroimaging and genetics data that are pooled across centers via meta- and mega-analytical approaches (Fig. 2).
The ENIGMA working groups’ chairs are composed of a selection of principal investigators (PIs) participating in the working group, who are also experts in the field. The chairs can be nominated or self-nominated and the ENIGMA director and central team discuss and approve such requests. In this case, the chairs of the ENIGMA-Sleep group have actively sought potential collaborators willing to contribute their data to this initiative, and the majority of recruitment has been achieved via pre-existing personal contacts and collaborations, as well as by reaching out to the members of sleep societies and other ENIGMA working groups. However, any interested researcher with a fitting dataset is welcome to join, and may do so by contacting the consortium or working group chairs. The contributing PIs signed the Memorandum of Understanding (MOU) accepting the terms and policies of the ENIGMA-Sleep working group for data sharing, research proposals, analysis, and publications. In addition, they filled in a form to report the types and quantity of their available neuroimaging/genetics and sleep measured data, as well as demographic characteristics of their samples. Each PI in the ENIGMA-Sleep working group can suggest a new project by filling out the proposal that would be initially reviewed by the chairs, and then distributed among PIs for discussion by the members in a virtual meeting. Once the proposal is approved, the project leader will get access to the relevant raw data or primary results from each site, with permission from the group members who are willing to participate in that project. The analyses can either be based on the established ENIGMA protocols (c.f. http://enigma.ini.usc.edu/protocols/ and (Lariviere et al., 2020)), or can be done using custom protocols specific to the research question.

Currently, the available data across sites include 20554 subjects from various sites with sleep diary and different questionnaires such as Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989), Insomnia Severity Index (ISI) (Bastien, Vallières, & Morin, 2001), Epworth Sleepiness Scale (ESS) (Johns, 1991), Global Sleep Assessment Questionnaire (GSAQ) (Roach et al., 2020), Berlin questionnaires (Netzer, Strohs, Netzer, Clark, & Strohl, 1999), Adolescent Sleep Wake Scale (ASWS) (LeBourgeois, Giannotti, Cortesi, Wolfson, & Harsh, 2005), Composite Scale of Morningness (CSM) (C. S. Smith, Reilly, & Midkiff, 1989), Evaluation List Insomnia Therapy (ELIT) (G. Kerkhof, 1999), Holland Sleep Disorders Questionnaire (HSDQ) (G. A. Kerkhof et al., 2013), Morningness-Eveningness questionnaire (MEQ) (Horne & Ostberg, 1976), Johns Hopkins Restless Legs Severity Scale (JHRLLS) (Allen & Earley, 2001), Restless Legs Syndrome-Diagnostic Index (RLS-DI) (Benes & Kohnen, 2009), Karolinska Sleep Questionnaire (KSQ) (Åkerstedt et al., 2002), Karolinska Sleepiness Scale (KSNS) (Åkerstedt & Gillberg, 1990), Diurnal Type Scale (DTS) (Torsvall & Akerstedt, 1980). The datasets include 4076 actigraphy and 4288 PSG recordings. In addition, we have 1187 healthy controlled subjects and 655 healthy subjects with experimental sleep deprivation, 1575 patients with insomnia
disorder, 132 patients with ADHD disorder, 1123 patients with OSA, and 2242 patients with restless leg syndrome and 269 patients with bipolar disorder and 226 patient with MDD and 15486 participants including Population-based samples. The overall neuroimaging data includes 10072 subjects with T1-weighted images, 6396 with functional magnetic resonance imaging (fMRI) including 4951 with resting-state and 1445 with task-based functional data, and 8006 with diffusion-tensor imaging (DTI) data. Details on the subjects sleep and neuroimaging data, within the participating cohorts within the ENIGMA-Sleep are summarized in Table 1.

5. Current projects
The projects proposed within the ENIGMA-Sleep framework will focus on functional, microstructural, and structural changes associated with sleep disorders and individual differences in sleep health. Multi-modal neuroimaging data available as a part of the consortium will allow us to probe biologically-specific biomarkers associated with sleep physiology.

- Neural correlates of insomnia disorder
Several structural and functional neuroimaging studies, using resting-state or cognitive and emotional tasks, have been conducted on patients with insomnia disorder. However, so far, the results of these studies appear to be largely inconsistent (Tahmasian, Noori, et al., 2018). Nonetheless, some reviews have highlighted the involvement of the salience and the default mode networks in altered emotion processing, hyperarousal and sleep-to-wake transitions in these patients (Bagherzadeh-Azbari et al., 2019; Khazaie et al., 2017; Spiegelhalder et al., 2015). Thus, the ENIGMA-Sleep group aims to perform large-scale between-group comparisons of structural and functional imaging findings in insomnia patients compared to healthy controls, to gain more detailed insights into neurobiology of insomnia disorder.

- Association between circadian rhythms and aging
Circadian rhythm is essential for mental health and cognitive ability and individuals with a disrupted circadian rhythm are at a greater risk for mental disorders, particularly MDD and bipolar disorder (McClung, 2007). For instance, a lower difference in activity profiles between daytime activity and nighttime activity increases the risk of mood disorder and leads to poorer subjective well-being (Lyall et al.,
In this project, structural and functional data are assessed in parallel to actigraphy and in-lab measurements of night-time (PSG) and daytime (circadian sleep-wake propensity PSG) measures, as well as assessment of drowsiness using Karolinska Drowsiness Test (KDT) (Åkerstedt & Gillberg, 1990), cortical excitability, and vigilance, in addition to cognitive phenotyping of healthy older adults. Thus, we aim to investigate the relationship between circadian rhythm, brain structure/function, gene and mental health, and then use mediation analysis and Bayesian network to access the underlying mechanisms that link circadian rhythm to the cognitive aging process.

- Neural correlates of sleep duration and quality in healthy subjects across lifespan

The prevalence of short sleep duration and poor sleep quality in the general population are noticeable, but little is known about the potential impact of such chronic sleep disturbances on the brain. Sleeping too little or too much can be detrimental to cognitive functioning, which begs the question of whether and how sleep duration affects brain function. It is also well-known that people are generally poor at assessing their actual sleep length, and there is often a large discrepancy between self-reported and objective measures of sleep - to such a degree that subjective and objective sleep parameters are believed to measure different constructs and present distinct biological underpinnings (Rezaie, Fobian, McCall, & Khazaie, 2018; Tahmasian et al., 2017). Leveraging the datasets of ENIGMA-sleep enables us to associate objective measures of naturalistic sleep (e.g., measured using actigraphy) and perceived sleep quality with brain activity and structure.

- Neural basis of selective vulnerability to lapses following sleep deprivation

Inter-individual differences in vigilance and visual attention have been observed in previous studies of human performance following acute sleep-deprivation (Chee et al., 2008; Chuah & Chee, 2008). Neuroimaging studies have shown that such differences between individuals may be explained by differences in task related activation (Chee & Chuah, 2008), functional connectivity (Wang, Ong, Patanaik, Zhou, & Chee, 2016; Yeo, Tandi, & Chee, 2015), dynamics and structural organization of the brain (Hawes et al., 2020; Poudel et al., 2018; Toppi et al., 2016). The ENIGMA-Sleep group aims to conduct neuroimaging mega- and meta-analyses on individuals undergoing sleep deprivation, by investigating the association between cortical morphological features (such as thickness and volume) or functional dynamics (from resting-state fMRI studies) with the frequency of performance lapses after sleep deprivation.

- Structural dysconnectivity in individuals with poor sleep quality or sleep disorders

This article is protected by copyright. All rights reserved
Understanding the structural connectivity alterations of healthy subjects with sleep impairment or patients with sleep disorders are important features in sleep medicine (Raikes et al., 2018; Rostampour et al., 2020). Diffusion tensor imaging (DTI) is a method to assess white-matter brain integrity and identify microstructural abnormalities. Here, we aim to perform tract-based spatial statistics (TBSS) (S. M. Smith et al., 2006) on the pooled multi-center neuroimaging data, based on the ENIGMA protocols, which uses a skeleton of white matter tracts for assessing statistical differences in regional fractional anisotropy (FA) values between healthy subjects with good or poor sleep quality/quantity and between healthy subjects and patients with sleep disorders. Next, the association between the subjective or objective sleep measurements and regional diffusion alterations will be assessed.

- Transdiagnostic neural correlates of sleep across mental illnesses

Sleep disturbances are prevalent symptoms in many neuropsychiatric disorders including, but not limited to, Alzheimer disease and dementia (Emamian et al., 2016; Peter-Derex, Yammine, Bastuji, & Croisile, 2019), Parkinson disease (Mantovani, Smith, Gordon, & O'Sullivan, 2018), PTSD (Ahmadi et al., 2020; Germain, 2013), major depressive disorder (Bagherzadeh-Azbari et al., 2019; Emamian, Khazaie, Okun, Tahmasian, & Sepehry, 2019; Murphy & Peterson, 2015), ADHD (Cortese, Faraone, Konofal, & Lecendreux, 2009), autism spectrum disorder (Kotagal & Broomall, 2012; Souders et al., 2017), or anxiety disorders (Baglioni et al., 2016; Cox & Olatunji, 2020). Such studies have a great impact on society and health policy makers to decrease the risk of neuropsychiatric disorders by improving the sleep quality and alerting clinicians to carefully screen for and treat sleep disorders. However, precise neural mechanisms of the link between these neuropsychiatric disorders and sleep are still poorly understood. In dementia, for example, it has been suggested that sleep apnea can increase the risk of Alzheimer disease through inducing hypoxia and inflammation, which in turn increases the concentration of amyloid-beta and tau proteins (Bucks et al., 2017; Ju, Lucey, & Holtzman, 2014; Rosenzweig et al., 2015). Moreover, monoamine system impairment and alterations within and between the salience and default mode networks have been suggested as the neurobiological link between depression and insomnia (Bagherzadeh-Azbari et al., 2019). In general, there is a clear need for collaboration between researchers in the ENIGMA-Sleep and other ENIGMA working groups to evaluate the neural basis of sleep disturbances in various neurological and mental illnesses using a transdiagnostic approach.
6. Challenges and opportunities for the ENIGMA-Sleep working group

Studying the neural correlates of sleep quality/quantity comes with its own unique challenges compared with other neuropsychiatric disorders. In particular, the small number of eligible included studies (<20) in the recent neuroimaging meta-analyses on insomnia (Jiang et al., 2020; Tahmasian, Noori, et al., 2018; Wu et al., 2020) or OSA (Huang et al., 2019; Shi et al., 2017; Tahmasian et al., 2016; Weng et al., 2014) were considerably lower than the ones for other psychiatric disorders such as depression (N = 97) (Gray, Müller, Eickhoff, & Fox, 2020) or obsessive compulsive disorder (N = 54) (Rasgon et al., 2017). In addition, a PubMed search for “functional magnetic resonance imaging” and (insomnia or OSA) in December 2020 retrieved 112 studies, while this figure is much higher for e.g., depression (n=2132), anxiety (n=1532), schizophrenia (n=1756), and (dementia or Alzheimer) (n=1227). The lower appeal of neuroimaging research in sleep disorders can be attributed to several reasons including (i) ignoring the importance of sleep disturbance in clinical practice and the resulting underdiagnosis of such disorders, (ii) lower priority for research funders and policy makers to support sleep research (Roach et al., 2020), and (iii) the costs and difficulties of objective sleep measurement (see below). The worldwide collaboration in the ENIGMA-Sleep may help individual centers to share their data and expertise to include more subjects, obtain more funding, apply sophisticated methodology, work together to answer upcoming questions, and finally alert our societies to the importance of sleep disturbance on human health and well-being.

The diversity of sleep measurement methods used in different sleep laboratories is an additional challenge for the ENIGMA-Sleep group. Self-report questionnaires such as PSQI (Buysse et al., 1989), ISI (Bastien et al., 2001), STOP-Bang (Chung, Abdullah, & Liao, 2016), ESS (Johns, 1991), and Berlin questionnaires (Netzer et al., 1999) are commonly used due to their wider availability and their ability to capture subjective sleep symptoms, which is important for e.g., insomnia disorder. These tools have medium to high diagnostic performance (Buysse et al., 1989; Ng et al., 2019), but could be susceptible to recall bias. Prospective sleep diaries are an inexpensive alternative to the questionnaires that could rectify the recall bias problem and also allow investigation of day to day variability of sleep, but similar to the questionnaires, they are also prone to misestimating objective aspects of sleep (e.g. sleep duration) (Van Den Berg et al., 2008). Although valid objective measurements in many psychiatric disorders are not available for diagnosis and phenomenology, objective sleep measurement does exist. PSG is the gold standard tool for the measurement of objective sleep parameters such as sleep duration and sleep efficiency, as well as diagnosis of sleep disorders (Douglas, Thomas, & Jan, 1992; Kushida et
This method is typically performed in the sleep laboratories by trained experts and detects sleep stages by simultaneous recording of brain activity, eye movements, jaw and leg movements, nasal airflow, respiratory effort, oxygen saturation, heart rhythms, and body position throughout the sleep-wake cycle (Douglas et al., 1992). However, despite some progress in making it more convenient and even ambulatory, it is still rather difficult, costly, time-consuming, often inaccessible worldwide, and inconvenient for many patients (Scott, Lack, & Lovato, 2020). Conventional ambulatory sleep measurement device i.e., actigraphy, is a more available/convenient alternative that has become increasingly popular in sleep and neuropsychiatric research (Sadeh, 2011; Tahmasian, Khazaie, Golshani, & Avis, 2013). An actigraph is a wearable gyro sensor, commonly worn as a wristwatch, that is suitable for longitudinal monitoring of sleep-wake patterns and circadian rhythms over days or weeks (Park & Choi, 2019), as well as measuring rest-activity fragmentation or locomotor activity dynamics over the night (Lim et al., 2011; Winnebeck, Fischer, Leise, & Roenneberg, 2018). Newer devices integrate sleep, heart rate and physical activity information to show how major life events like the recent COVID-19 pandemic objectively affect all three (Ong et al., 2020). Furthermore, some large-scale databases have actigraphy data, which allows to link brain level parameters with objective sleep patterns in a large number of people. Actigraphy has been widely used to study rest-activity patterns and sleep, with a growing interest in the analysis of large population-based samples. Within this perspective, efforts have been made to develop open-source toolboxes that allow users to preprocess, visualize and quantify various properties of the rest-activity rhythms using actigraphy data from various brands of devices, as well as to perform more advanced signal processing analyses (Hammad et al., 2020). However, actigraphy has low specificity and tends to overestimate sleep time in comparison to PSG, and unlike PSG, cannot discriminate between different stages of sleep (Park & Choi, 2019), for which an alternative is multimodal wearable sleep sensors (Boe et al., 2019). Taken together, an important challenge in the field of sleep research and neuroimaging is the lack of widely accessible, convenient and inexpensive, yet highly accurate sleep measurement methods. The ENIGMA-Sleep can provide a chance to investigate novel research questions based on similar subjective or objective sleep data across sites that are not possible when only analyzing data from a single study.

In addition, although recently there has been remarkable advances in facilitating open data sharing (White, Blok, & Calhoun, 2020), traditionally not many researchers are willing to share their raw data (Krawczyk & Reuben, 2012; Wicherts, Borsboom, Kats, & Molenaar, 2006) due to legal/ethical prohibitions or other reasons. The reluctance of researchers to share data might be due to lack of time/resources for curating and documenting the data such that it can be properly used by others, being
unable to receive proper credit/recognition for the shared data, or worries about being scooped by other teams who may be able to publish prior to them (White et al., 2020). As a result, and to mitigate these problems, within the ENIGMA consortium, we are developing guidelines and protocols for data sharing to facilitate the curation and documentation of the data. In addition, to avoid legal/personal problems with raw data sharing, in the meta-analytic approach, we ask each site to share the first- or second-level statistics obtained using pre-defined analysis protocols, and in the mega-analytic approach, when we do need raw data for a specific question, we will acquire it following careful ethical considerations and based on the ENIGMA guidelines and institution/regional laws of data sharing (e.g. General Data Protection Regulation (GDPR) in the European Union) ensuring anonymity of the subjects. In addition, the PIs have complete control over their own data, and thus actively agree to participate in the individual projects they wish to. Members are credited for their contribution by having authorship in resulting publications (Thompson et al., 2020).

The heterogeneity of imaging data is another challenge for the ENIGMA-Sleep group. There are inevitable variations in data acquisition in terms of different field strengths (1.5, 3, or 7T), scanning sequences, type of acquired tasks, and preprocessing (Bas-Hoogendam et al., 2020; Dennis et al., 2020; Schmaal et al., 2020; van den Heuvel et al., 2020). However, applying unified preprocessing and first- and second-level analysis pipelines using the available ENIGMA protocols can help decrease further inference divergence and replicability/reproducibility issues that is an important issue in neuroimaging currently (Botvinik-Nezer et al., 2020; Kharabian Masouleh, Eickhoff, Hoffstaedter, & Genon, 2019; Poldrack, 2008, 2019). Moreover, the clinical phenotypes of study samples and their in-/exclusion criteria are heterogeneous in terms of diagnosis criteria, age and gender of subjects, severity and stage of the disorders, comorbidities, and pharmacological or non-pharmacological treatments. Our approach for addressing this problem in the ENIGMA-Sleep is to use unified selection criteria for the samples and to control for the covariates/comorbidities properly.

Our current datasets mostly include cross-sectional data, and we will need more longitudinal data to identify trajectories of sleep disorders and how they are affected by the specific treatments. Moreover, on the one side, the ENIGMA projects can generate hypotheses that can be further tested in the single studies. On the other hand, the ENIGMA projects can also be used for validating findings from single studies in a larger setting.

Last but not least, there are few imaging-genetic studies investigating the link between genotypes and brain structures in sleep disorders (Jansen et al., 2019; Tahmasian et al., 2020; Takeuchi...
et al., 2018). However, finding individual imaging samples on sleep disorders with genotyping data (e.g., GWAS studies) is confined and mostly limited to a particular country and therefore, cannot assess the variety of genotypes across different populations. In addition, these studies have often identified sleep problems using subjective sleep questionnaires or even a single question, rather than objective measurements or diagnosing sleep disorders according to standard criteria. This highlights a huge gap between the numbers of genetic data on sleep studies in comparison with other neuropsychiatric disorders.

7. Conclusion

In order to truly elucidate the neural correlates of sleep quality/quantity in the general population and their changes across the lifespan, brain alterations after sleep deprivation, as well as structural and functional abnormalities in patients with sleep disorders, or the neural correlates of sleep disturbances in various neuropsychiatric disorders, large-scale meta- and mega-analysis studies are needed. In this article, we have discussed some of the challenges, opportunities, as well as the road map of the newly-established ENIGMA-Sleep group. The core purpose of this initiative is to unite sleep clinicians/scientists across different countries to work together and join us in this exciting initiative (http://enigma.ini.usc.edu/ongoing/enigma-sleep/). Moreover, as many neuropsychiatric disorders present with sleep disturbance symptoms, this group could work with other ENIGMA working groups and other neuroimaging cohorts on various mental illnesses. This review highlights a clear need for the global sharing of cross-sectional and longitudinal imaging-genetic data, and the development of harmonized data collection and analysis approaches for studying sleep and its disorders. We hope that ENIGMA-Sleep will advance the field of sleep medicine by obtaining robust and replicable results using large-scale datasets.

References


This article is protected by copyright. All rights reserved


This article is protected by copyright. All rights reserved


This article is protected by copyright. All rights reserved


This article is protected by copyright. All rights reserved


This article is protected by copyright. All rights reserved


This article is protected by copyright. All rights reserved


This article is protected by copyright. All rights reserved


This article is protected by copyright. All rights reserved


This article is protected by copyright. All rights reserved


This article is protected by copyright. All rights reserved


**Figure Legends**

**Figure 1.** Map of participating institutes in ENIGMA-Sleep working group across 15 countries.

**Figure 2.** An overview of neuroimaging tools for assessing functional and structural pathways underpinning sleep physiology. Primary sleep circuit is located in the sub-cortical regions within brain-stem and thalamus. The cortical regions including dorsolateral prefrontal cortex (DLPFC), Basal Forebrain (BF), Anterior Cingulate Gyrus (ACG),
Intraparietal Sulcus (IPS), and Visual Cortex and direct afferent/efferent connections to sub-cortical sleep regions may be important for cortical regulation of sleep physiology.
<table>
<thead>
<tr>
<th>Sample #</th>
<th>Country</th>
<th>Institution</th>
<th>Diagnosis</th>
<th>Gender Ratio</th>
<th>N (%)</th>
<th>Disorder</th>
<th>F/M</th>
<th>Field strength (T)</th>
<th>Type of MRI data</th>
<th>Objective sleep assessment</th>
<th>Sleep questionnaires and genetic information</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Kermanshah, Iran</td>
<td>KUMS</td>
<td>Insomnia</td>
<td>1.660</td>
<td>57</td>
<td>7/11</td>
<td></td>
<td>1.5</td>
<td>T1-w, DTI, rs-fMRI</td>
<td>Sleep questionnaires and genetic information</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Milano, Italy</td>
<td>IRCCS</td>
<td>Bipolar</td>
<td>0.620</td>
<td>142</td>
<td>7/105</td>
<td></td>
<td>1</td>
<td>T1-w, DTI, rs-fMRI</td>
<td>Sleep questionnaires and genetic information</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Singapore</td>
<td>NUS</td>
<td>Healthy controls</td>
<td>0.500</td>
<td>52</td>
<td>3/52</td>
<td></td>
<td>1.5</td>
<td>T1-w, DTI, rs-fMRI</td>
<td>Sleep questionnaires and genetic information</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Greifswald, Germany</td>
<td>DIPUMG</td>
<td>Insomnia disorders</td>
<td>0.850</td>
<td>1237</td>
<td>8/15</td>
<td></td>
<td>0.9</td>
<td>T1-w, DTI, rs-fMRI</td>
<td>Sleep questionnaires and genetic information</td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td>Institution</td>
<td>Measure</td>
<td>N</td>
<td>Gender</td>
<td>Age</td>
<td>BD</td>
<td>MDD</td>
<td>ADHD</td>
<td>OSA</td>
<td>Insomnia</td>
<td>Sleep restriction</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>---------</td>
<td>-----</td>
<td>--------</td>
<td>-----</td>
<td>----</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>----------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Stockholm, Sweden</td>
<td>Karolinska Institutet</td>
<td>Sleep restriction in healthy participants</td>
<td>1.047</td>
<td>M</td>
<td>84</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Stockholm, Sweden</td>
<td>Karolinska Institutet</td>
<td>Sleep deprivation in healthy participants</td>
<td>0.650</td>
<td>M</td>
<td>47</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rotterdam, Netherlands</td>
<td>Erasmus MC</td>
<td>Population-based sample</td>
<td>1.446</td>
<td>M</td>
<td>2496</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Freiburg, Germany</td>
<td>ULMC</td>
<td>Insomnia</td>
<td>1.770</td>
<td>M</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Freiburg, Germany</td>
<td>ULMC</td>
<td>Healthy controls</td>
<td>1.300</td>
<td>M</td>
<td>47</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Amsterdam, Netherlands</td>
<td>NINS</td>
<td>Insomnia</td>
<td>2.984</td>
<td>M</td>
<td>87</td>
<td>1.5</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Amsterdam, Netherlands</td>
<td>NINS</td>
<td>Healthy controls</td>
<td>2.406</td>
<td>M</td>
<td>76</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>France</td>
<td>Neumagen</td>
<td>Bipolar</td>
<td>1.000</td>
<td>M</td>
<td>28</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>France</td>
<td>Neumagen</td>
<td>Healthy controls</td>
<td>0.867</td>
<td>M</td>
<td>28</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Melbourne, Victoria, Australia</td>
<td>Deakin University</td>
<td>ADHD</td>
<td>0.377</td>
<td>M</td>
<td>84</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Melbourne, Victoria, Australia</td>
<td>Deakin University</td>
<td>Healthy controls</td>
<td>0.900</td>
<td>M</td>
<td>76</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Amsterdam, Netherlands</td>
<td>AMC</td>
<td>ADHD</td>
<td>0.000</td>
<td>M</td>
<td>48</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Houston, Texas, Texas</td>
<td>UTHSC</td>
<td>BD, MDD</td>
<td>1.829</td>
<td>M</td>
<td>99</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Houston, Texas, Texas</td>
<td>UTHSC</td>
<td>Healthy controls</td>
<td>1.579</td>
<td>M</td>
<td>49</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Location</td>
<td>Institution</td>
<td>Disease</td>
<td>PHQ-9</td>
<td>BDI-I</td>
<td>FAS-10</td>
<td>TAS-20</td>
<td>CDSS</td>
<td>LIS</td>
<td>PVT</td>
<td>HMEQ</td>
<td>BIS</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------</td>
<td>--------------------------</td>
<td>-------</td>
<td>-------</td>
<td>--------</td>
<td>--------</td>
<td>------</td>
<td>-----</td>
<td>-----</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>California, United States</td>
<td>UCSF</td>
<td>Healthy controls</td>
<td>1.895</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Groningen, Netherlands</td>
<td>UG</td>
<td>MDD</td>
<td>2.833</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Groningen, Netherlands</td>
<td>UG</td>
<td>Healthy controls</td>
<td>2.429</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brisbane, Australia</td>
<td>UQ</td>
<td>Healthy controls</td>
<td>0.936</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maryland, United States</td>
<td>UMSOM</td>
<td>Family-based recruitment sample, focused on cross-diagnostic illnesses research</td>
<td>1.363</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melbourne, Victoria, Australia</td>
<td>ACU</td>
<td>Sleep deprivation in healthy participants</td>
<td>1.000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melbourne, Victoria, Australia</td>
<td>ACU</td>
<td>Healthy Controls</td>
<td>1.030</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oslo, Norway</td>
<td>OLH</td>
<td>Sleep deprivation in healthy participants</td>
<td>0.600</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oslo, Norway</td>
<td>OLH</td>
<td>Healthy Controls</td>
<td>0.600</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1. ENIGMA-Sleep samples characteristics and the available imaging, genetics and sleep data. ACU: Australian Catholic University; AHI: Apnea Hypopnoea Index; AMC: Academic Medical Center; ASWS: Adolescent Sleep Wake Scale; BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; BIS: Bergen Insomnia Scale; BRIEF-A: Behavior Rating Inventory of Executive Function for Adults; CAS: Confirmation of Acceptance for Studies; CDRS-R: Children’s Depression Rating Scale, Revised; CFS: Chalder Fatigue Scale; CSM: Composite Scale of Morningness; CTQ: Childhood Trauma Questionnaire; DPPUMG: Department of Psychiatry and Psychotherapy, University Medicine Greifswald; DSM-V: Diagnostic and Statistical Manual of Mental Disorders; DTS: Diurnal Type Scale; ELIT: Evaluation List Insomnia Therapy; Erasmus MC: Erasmus University Medical Center; ESS: Epworth Sleepiness Scale; FAS: Fatigue Assessment Scale; FSS: Fatigue Severity Scale; GIGA-CRC: GIGA-Cyclotron Reaserch Center in Vivo Imaging; 

This article is protected by copyright. All rights reserved
**ASL/PET**
- Cerebral perfusion/metabolism changes associated with sleep disorders.
- Cerebral perfusion changes associated with loss of vigilance.

**DWI**
- Delineation of white matter tracts connecting thalamus, midbrain, and brain-stem to the cortex.
- Assessment of Microstructural Integrity of White Matter

**BOLD fMRI**
- Functional connectivity of large-scale cortical networks.
- Sleep-stage specific changes in BOLD fMRI.
- Impact of sleep on brain function.

**MRI-SPECT**
- Metabolic alterations
- Neuroaxonal markers e.g., N-acetyl-aspartate (NAA).

This article is protected by copyright. All rights reserved
Title:
ENIGMA-Sleep: Challenges, opportunities, and the road map

Date:
2021-04-28

Citation:

Persistent Link:
http://hdl.handle.net/11343/298489